Upon joining the study, participants will be informed about the trial’s purpose, procedures, and potential risks and benefits. Participants will be required to sign an informed consent form, confirming their understanding and willingness to participate.

Participants will undergo an initial assessment to confirm eligibility. This includes providing a sample of tumor tissue for analysis and undergoing various tests to assess overall health and organ function.

In Part A, participants will receive a combination of the study drug GSK5733584 with other anti-cancer medications such as dostarlimab, carboplatin, cisplatin, and bevacizumab. All medications will be administered through an intravenous infusion, which means they will be given directly into a vein.

The dosage and frequency of administration will be determined based on safety and tolerability. Participants will be closely monitored for any side effects or adverse reactions.

In Part B, the focus will be on evaluating the effectiveness of the study drug GSK5733584 in combination with other treatments compared to using GSK5733584 alone. Participants will continue to receive medications through intravenous infusion.

The duration of this phase will depend on the participant’s response to the treatment and any side effects experienced.

Throughout the trial, participants will have regular check-ups to monitor their health and the effects of the treatment. This includes blood tests, imaging scans, and assessments of any symptoms or side effects.

Participants will be required to report any new symptoms or changes in their condition to the study team promptly.

At the end of the treatment period, participants will undergo a final assessment to evaluate the overall impact of the treatment on their condition.

Participants will be informed about the next steps, including any follow-up care or additional treatments that may be necessary.